This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

D. Xeno Rasmusson, PhD
Alzheimer's Disease Research Center The Johns Hopkins University School of Medicine Room 1B82 5501 Hopkins Bayview Circle Baltimore, MD 21224

Gloria Dal Forno, MD; Jason Brandt, PhD; Juan Troncoso, MD; Claudia H. Kawas, MD
Baltimore

Arch Neurol. 1996;53(11):1095.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In reply

We thank Corder and colleagues for their comments on our recent study¹ and we are pleased that they agree with our conclusion that ApoE genotype does not appear to significantly influence rate of cognitive decline in AD. In their letter, Corder et al also raised 2 other issues regarding our study.

The authors correctly note that the study by Corder et al² did not report "longer survival in 4 carriers." In addition to the study by van Duijn et al,³ those findings should have been correctly attributed to DeKosky et al⁴ and not to Corder et al,² as indicated by the reference numbers in the text of our article. We apologize for the confusion this oversight created.

Corder et al state that we "argue against the existence of an 4 gene-dose effect on the risk of becoming affected [with AD]." Our study on rate . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?